Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 1, Double-blind, Single and Multiple-Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMS1620 in Healthy Participants

NCT07811089 is registered in ClinicalTrials.gov with OMass Therapeutics Australia Proprietary Ltd as lead sponsor.

NCT NCT07811089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 1, Double-blind, Single and Multiple-Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMS1620 in Healthy Participants
Lead sponsor
OMass Therapeutics Australia Proprietary Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2027
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia (cah)